Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27820726 | 0.82 | CYP19A1 (0.71) | EPHX2CYP19A1ALDH1A1TAAR1HPGD | |
| SCHEMBL1301606 | 0.82 | CYP19A1 (0.71) | EPHX2CYP19A1ALDH1A1TAAR1HPGD | |
| SCHEMBL11631841 | 0.81 | CYP19A1 (0.56) | EPHX2CYP19A1ALDH1A1POLBHPGD | |
| SCHEMBL19153862 | 0.81 | CYP19A1 (0.55) | EPHX2CYP19A1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5049441 | 0.80 | CYP19A1 (0.71) | EPHX2CYP19A1ALDH1A1HPGDKDM4E | |
| SCHEMBL3964624 | 0.79 | CYP19A1 (0.54) | CYP19A1MAPTPOLBSIGMAR1 | |
| Cyclohexanol SCHEMBL9103387 | 0.78 | EPHX2 (0.62) | EPHX2MAPTCTBP2SIGMAR1GLA | |
| SCHEMBL31244291 | 0.78 | CTBP2 (0.56) | EPHX2ALDH1A1CTBP2SMN1; SMN2SIGMAR1 | |
| SCHEMBL6761969 | 0.77 | CYP19A1 (0.66) | EPHX2CYP19A1ALDH1A1GLAHPGD | |
| SCHEMBL11666873 | 0.77 | CYP19A1 (0.54) | EPHX2CYP19A1ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646026-B1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8618139-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | EPHX2 2514/4885CYP19A1 4008/4885ALDH1A1 3252/4885 |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | EPHX2 2514/4885CYP19A1 4008/4885ALDH1A1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.